Simplify Logo

Full-Time

Head of AI Structural Biology Research

Confirmed live in the last 24 hours

Absci

Absci

51-200 employees

Biotech company specializing in protein production

Biotechnology

Compensation Overview

$245k - $330kAnnually

+ Equity Package + Bonus

Senior, Expert

New York, NY, USA + 1 more

More locations: Vancouver, WA, USA

Hybrid role with options for remote work or onsite presence in New York, NY or Vancouver, WA.

Category
Computational Biology
Genomics
Biology & Biotech
Required Skills
Data Structures & Algorithms
Requirements
  • Ph.D. in Computer Science, Machine Learning, Computational Biology, or a related field
  • 5+ years of experience in AI/ML research, with at least 2 years in a technical lead role
  • Strong publication record or demonstrated expertise in areas such as generative AI, deep learning, or computational biology
  • Experience applying AI techniques to biological problems, particularly in protein design or drug discovery
  • Proven track record of leading successful AI research projects and translating research into practical applications
  • Excellent communication skills, able to explain complex AI concepts to diverse audiences
  • Strong problem-solving skills and ability to think critically about AI research challenges
Responsibilities
  • Lead and manage a team of 4-6 AI/ML researchers, providing technical guidance and fostering a culture of innovation
  • Oversee the development and implementation of novel AI/ML models and algorithms, particularly in areas like amino acid sequence generation and 3D protein structure prediction
  • Collaborate with interdisciplinary teams of lab scientists, program managers, and software engineers to define research objectives and translate findings into practical applications
  • Manage and prioritize multiple research projects, ensuring alignment with Absci's goals and timelines
  • Contribute to the architectural design of AI systems, balancing research exploration with production-grade implementations
  • Provide thought leadership for the team, particularly in methods relevant to antibody engineering
  • Mentor team members, fostering their growth as AI researchers and engineers
  • Represent Absci's AI research capabilities at conferences, in publications, and in collaborations with academic and industry partners
  • Instilling and ensuring adherence to the company's core values

AbSci focuses on improving protein expression and biomanufacturing in the biotech industry. Its main product is an advanced protein expression platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system, allowing for better control over protein production rates. This results in higher quality and more efficient drug manufacturing. A key feature of AbSci's offerings is SoluPure, a method that simplifies protein purification without chromatography, speeding up the production process and reducing costs. AbSci's workflow can create cell lines that produce active proteins in as little as three months, which is much faster than traditional methods. Unlike its competitors, AbSci aims to replace older mammalian expression systems with its more efficient solutions. The company's goal is to enhance drug discovery and manufacturing processes for pharmaceutical and biotech companies, ultimately transforming the production of biologics.

Company Stage

IPO

Total Funding

$324.3M

Headquarters

Vancouver, Washington

Founded

2011

Growth & Insights
Headcount

6 month growth

2%

1 year growth

-2%

2 year growth

-3%
Simplify Jobs

Simplify's Take

What believers are saying

  • AbSci's recent $86M public stock offering and strategic partnerships, such as with AstraZeneca, highlight strong financial backing and growth potential.
  • The company's ability to generate cell lines producing active protein products in as little as three months accelerates drug development timelines, offering significant time and cost savings.
  • AbSci's collaboration with PrecisionLife to develop an AI-enabled drug pipeline demonstrates their commitment to innovation and addressing unmet medical needs.

What critics are saying

  • The biotech industry is highly competitive, and AbSci must continuously innovate to maintain its edge over established and emerging competitors.
  • Relying heavily on strategic partnerships and collaborations could pose risks if these relationships falter or fail to deliver expected outcomes.

What makes Absci unique

  • AbSci's SoluPure technology offers a chromatography-free purification method, significantly reducing bottlenecks in protein production compared to traditional techniques.
  • Their advanced protein expression platform with a semi-oxidizing cytoplasm and dual inducible promoter system allows for precise control over protein production rates, setting them apart from competitors.
  • AbSci's integration of generative AI in drug discovery and biomanufacturing positions them uniquely in the biotech industry, combining cutting-edge technology with traditional biopharmaceutical processes.